CIPLA LIMITED

Eli Lilly plans to launch Tirzepatide (Mounjaro) in India in 2025, targeting type 2 diabetes and obesity. The company is optimistic about the Indian market due to rising disease burdens and health expenditure. Mounjaro's global Q3 2024 sales were over $3.1 billion, and pricing in India will be competitive, reflecting its efficacy.

The generic pharmaceuticals market was valued at USD 424.98 billion in 2024 and is projected to reach USD 874.63 billion by 2033, driven by cost-effective medications, rising chronic disease prevalence, government support, and advancements in manufacturing technologies.

Novo Nordisk accelerates Wegovy launch in India to 2025, aligning with Eli Lilly's Mounjaro. Both drugs are GLP-1 receptor agonists aiding weight loss. India's large population and rising obesity create a significant market, but faces competition from local generic drug manufacturers.

Novo Nordisk's India team pushes for an earlier launch of Wegovy, fearing to fall behind Eli Lilly in the weight-loss market. Novo plans to introduce Wegovy in India in 2026, but the India team proposed a 2024 launch. Novo received regulatory approval for injectable semaglutide in India in late 2022.

The antibiotics and antimycotics market is projected to reach $91.54 billion by 2031, driven by infectious disease prevalence and R&D initiatives. Key players include Pfizer, Novartis, and Sanofi. North America leads in revenue, with APAC expected to show highest growth.

Orchid Pharma reports 26% growth in PAT for Q2 FY2024-25, with sales at Rs. 222.7 crores and EBITDA at Rs. 37.5 crores. Cumulative H1 sales reached Rs. 467.1 crores, up 22% YoY. Key milestones include the 7ACA project and the Indian launch of ORBLICEF, an innovative drug. Orchid AMS division launched to enhance antimicrobial stewardship. Enmetazobactam sales commenced in Europe, with U.S. expansion anticipated.

Lupin Pharmaceuticals plans to launch generic GLP-1 receptor agonists in 2026, targeting India, South Africa, Latin America, the Philippines, and Eastern Europe. The company aims to capitalize on patent expiries by combining in-house development with licensing partnerships. Competitors like Cipla, Dr. Reddy’s, Wockhardt, and Mankind Pharma are also entering the GLP-1 market, driven by high demand for diabetes and obesity treatments.

SEC recommends market authorisation for MSN Laboratories' generic Pitolisant tablets for narcolepsy, with conditions including a phase-IV trial. The drug, a generic of Harmony Biosciences' Wakix, addresses EDS and cataplexy, with a novel mechanism and unmet need. MSN must include CYP2D6 Genotype determination in prescribing info. Harmony Biosciences holds a US patent until 2029 and sued MSN for patent infringement.

The global liposomal doxorubicin market reached USD 1.3 billion in 2023 and is projected to grow at a CAGR of 5.1% to exceed USD 2 billion by 2032, driven by rising cancer incidence, advancements in nanotechnology, and favorable regulatory approvals. Key challenges include high treatment costs, adverse effects, and stringent regulatory requirements. Opportunities lie in emerging markets, ongoing R&D, and collaborations. Market segmentation includes drug formulations, applications, end users, and regions.